Clinical trials: Histological Response
Renal Cell Cancer
Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response
This exploratory clinical study is designed to obtain pre-therapeutic imaging assessments in 20 evaluable patients with metastatic renal cell cancer (RCC) and an early post therapy assessment at baseline and at various early time…
- Trial name
- NCT00694096
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Utah
Malignant Melanoma Stage III, Malignant Melanoma Stage IV
IL15 Dendritic Cell Vaccine for Patients With Resected Stage III (A, B or C) or Stage IV Melanoma
The purpose of the study is to gather data on feasibility as well as immune and clinical efficacy of of a dendritic cell vaccine using IL15 in patients with resected stage III or stage IV melanoma
- Trial name
- NCT01189383
- Testing
- IL15-DC Vaccine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Baylor Research Institute
Non-Hodgkin's Lymphoma
A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's Lymphoma
This study will evaluate the efficacy and safety of MabThera/Rituxan in patients with relapsed low-grade centroblastic centrocytic non-Hodgkin's lymphoma.
- Trial name
- NCT01998893
- Testing
- rituximab [MabThera/Rituxan]
- Where
- 11 sites in Germany
- Volunteers
- 38 people
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma
Immunophenotyping of Plasma Cells and Immune Effector Cells in Peripheral Whole Blood and Bone Marrow Samples From Multiple Myeloma (MM) Patients
The objective of this study is to evaluate the immune profile of plasma cells and immune effector cells in paired peripheral whole blood and bone marrow samples from MM patients by standardized flow cytometry.
- Trial name
- MYELOME-MM (NCT05428163)
- Testing
- Biological sampling
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Chronic Myelocytic Leukemia
Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients
This study is conducted in patients with newly diagnosed CP CML (Chronic Phase Chronic Myeloid Leukemia) who have achieved EMR (< 10% IS BCR-ABL) at 3 months after first line treatment with dasatinib.
- Trial name
- NCT04150471
- Testing
- RQ-PCR(Real-time Quantitative Polymerase chain reaction) RNA Analysis
- Where
- South Korea
- Volunteers
- 79 people
- Sponsor
- Seoul St. Mary's Hospital
Metastatic Renal Cell Carcinoma
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
This phase II open label trial randomized patients who completed the induction with nivolumab plus ipilimumab without complete response or progressive disease will be randomized 1:1 to receive axitinib in addition to nivolumab…
- Trial name
- AxIn (NCT05817903)
- Testing
- Axitinib, Nivolumab
- Where
- 23 sites in Italy
- Volunteers
- 118 people
- Sponsor
- Consorzio Oncotech
Leukemia
G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission
RATIONALE: Giving colony-stimulating factors, such as G-CSF, helps stem cells move from the bone marrow to the blood so they can be collected and stored until transplant.
- Trial name
- NCT00233961
- Testing
- filgrastim
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Melanoma (Skin)
Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma
RATIONALE: Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about changes that may occur in DNA and identify biomarkers related to cancer, and may help…
- Trial name
- NCT00897546
- Testing
- laboratory biomarker analysis
- Volunteers
- 1,716 people, healthy volunteers welcome
- Sponsor
- ECOG-ACRIN Cancer Research Group
Pre-Eclampsia; Mild, Gestational Hypertension
Effect of RIC on BP and Inflammatory Response in Women With Pre-eclampsia
The aim of this pilot cohort study is to investigate whether treatment with remote ischemic conditioning (RIC) has a beneficial effect on blood pressure as well as the immune system in pregnant women with newly diagnosed…
- Trial name
- NCT03323762
- Testing
- Remote Ischaemic Conditioning (RIC)
- Where
- 3 sites in Denmark
- Volunteers
- 10 people
- Sponsor
- University of Aarhus
Head and Neck Squamous Cell Carcinoma
Immune Response Evaluation to Curative Conventional Therapy
The IRECT trial is a non-interventional, prospective clinical trial using modern immune monitoring techniques over the course of the standard of care for HNSCC.
- Trial name
- IRECT-01 (NCT03053661)
- Volunteers
- 22 people
- Sponsor
- University of Ulm
T-LGL Leukemia, NK-LGL Leukemia
Thalidomide for the Symptomatic Large Granular Lymphocytic Leukemia
There is currently no standard first-line treatment for LGLL. The investigators used the TPM regimen (thalidomide + prednison + methotrexate ) to treat LGLL since 2020, enrolling a total of 54 patients and achieving an overall…
- Trial name
- NCT06530576
- Testing
- Thalidomide and methotrexate
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Leiomyomas
Diffusion -and Perfusion Weighted MRI for Response Prediction of Symptomatic Leiomyomas Following Uterine Artery Embolization
It is known that volumetric response of leiomyomas following uterine artery embolization correlates well with patients clinical outcome.
- Trial name
- NCT01514617
- Testing
- Diffusion -and perfusion weighted MRI including iv contrast agent injection
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Peripheral T Cell Lymphoma
Genotype-guided Treatment in Newly Diagnosed PTCL
This study includes Phase I and Phase II stages. Phase I is an open-label trial to confirm RP2D of oral targeted agents in three genetic subtypes.
- Trial name
- THEORY (NCT05675813)
- Testing
- CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Ruijin Hospital
Ewing Sarcoma, Osteosarcoma
Osteosarcoma and Ewing Sarcoma Treatment Response Assessment With Functional MRI Imaging in Children and Young Adults
The purpose of the study was to investigate whether functional MRI imaging (diffusion weighted imaging) is useful for monitoring the therapeutic response of bone sarcomas in children and young adults.
- Trial name
- FUBEO (NCT01780779)
- Testing
- MRI
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Head and Neck Cancer
A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCC
RATIONALE: Gathering disease-related information from medical charts of patients with primary head and neck cancer who have undergone neck dissection after complete response to chemotherapy and radiation therapy may help doctors…
- Trial name
- NCT00483821
- Testing
- medical chart review
- Where
- 3 sites in United States
- Volunteers
- 165 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Chronic Myeloid Leukemia
Imatinib and BL-8040 (Novel Anti CXCR4 Antagonist) for Improving Molecular Response in Chronic Myelogenous Leukemia
The aim of the study is to test the safety and efficacy of BL-8040 (a CXCR4 antagonist) in improving the response to imatinib in CML patients not achieving an optimal response with imatinib alone.
- Trial name
- NCT02115672
- Testing
- BL-8040
- Where
- Israel
- Sponsor
- Sheba Medical Center
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-I
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-I (NCT03656549)
- Testing
- Pemetrexed + oral folinic acid rescue
- Where
- 6 sites in Netherlands
- Volunteers
- 6 people
- Sponsor
- Radboud University Medical Center
Non Functioning Pancreatic Endocrine Tumor
Clinical Effectiveness of Serum Chromogranin A Levels on Diagnostic of Pancreatic Neuroendocrine Tumors
Chromogranin A (CgA) is a glycoprotein with a molecular weight of 49 to 52 kDa produced by chromaffin cells of the adrenal medulla, enterochromaffin-like (ECL) cells, and endocrine cells of the stomach and pancreas, and it is the…
- Trial name
- CgA (NCT02759718)
- Testing
- Chromogranin A
- Volunteers
- 111 people
- Sponsor
- Asan Medical Center
Osteosarcoma, Neoplasms, Connective Tissue
Neoadjuvant Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors
Two cycles of neoadjuvant three-component chemotherapy according to the MAP prototoc: Doxorubicin 25 mg / m2 IV on days 1-3, Cisplatin 120 mg / m2 IV on day 1 against the background of hyperhydration.
- Conditions
- Osteosarcoma, Neoplasms, Connective Tissue, Neoplasms, Connective and Soft Tissue, Sarcoma
- Trial name
- NCT05057130
- Testing
- Doxorubicin, Cisplatin, Methotrexate, Doxorubicin, Cisplatin
- Where
- Russia
- Volunteers
- 50 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Metastatic Melanoma
Ipilimumab in Patients With Advanced Melanoma and Spontaneous Preexisting Immune Response to NY-ESO-1
This is an Open-label, single-arm, phase II study of ipilimumab in patients with spontaneous preexisting immune response to NY-ESO-1.
- Trial name
- CTLA4 NY-ESO-1 (NCT01216696)
- Testing
- ipilimumab
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- National Center for Tumor Diseases, Heidelberg
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.